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A 64-year-old male was diagnosed with malignant pleural mesothelioma (MPM) in June 2006
after complaining of dyspnoea and a persistent cough. In July 2006 the patient underwent talc
pleurodesis and started first-line chemotherapy with cisplatin associated with pemetrexed
(Alimta). At the end of the third chemotherapy cycle the disease was stable and no significant
drug toxicity was recorded. The patient progressed through another three cycles under the
same treatment schedule. Restaging at the end of the sixth cycle confirmed a stable disease
and the patient started follow-up. In January 2007, further restaging showed disease progres-
sion and the patient was enrolled in a phase I clinical trial involving a continuous infusion of
pemetrexed until at a dose of 100 mgm2 at day one. After 8 days the patient was referred
to the Accident and Emergency Department for acute dyspnoea and a fever of 38.5 C. A high
resolution CT-scan of the thorax showed diffuse, bilateral areas of ground glass attenuation
with a patchy distribution. A 13-day broad-spectrum antibiotic therapy did not achieve any
clinical and/or radiological improvement of respiratory abnormalities, and for this reason
a bronchoscopy, with a fluoroscopic-guided transbronchial lung biopsy (TBB), and a bronchoal-
veolar lavage (BAL), were performed. BAL cultures for common bacteria, acid fast bacilli and
fungi, as well as vial cultures and/or immunofluorescent tests for viruses (cytomegalovirus,
adenovirus, herpes simplex virus, syncytial respiratory virus, influenzae and parainfluenzae
viruses) and Legionellae, proved negative. Examination of BAL cytospin preparations, stained
by both Diff-Quick and Papanicolaou methods, showed cuboidal hyperplastic/dysplastic cells
(diffuse alveolar damage cells) whilst no malignant cells, viral inclusions, fungi, or Pneumocys-
tis jiroveci cysts were identified. The TBB showed remnants of jaline membranes in the alve-
olar spaces along with granulation tissue partly obliterating the alveolar spaces, and slightt of Respiratory Diseases, Morgagni-Pierantoni Hospital, Via Forlanini 10, 47900 Forlı` (FC), Italy.
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268 G. Genestreti et al.thickening of the interalveolar septa. Plump elongated reactive type II pneumocytes covering
the alveolar septa were also numerous. A regimen of 200 mg methylprednisolone once a day
was started and a partial remission of clinical and radiological abnormalities was achieved.
Based on our clinical and radiological findings we therefore conclude a possible diagnosis of
drug-induced toxicity by pemetrexed chemotherapy in continuous infusion.
ª 2008 Elsevier Ltd. All rights reserved.Figure 1 High resolution CT-scan of the thorax: diffuse,
bilateral areas of ground glass attenuation with a patchy
distribution.Case report
A 64-year-old male was diagnosed with malignant pleural
mesothelioma (MPM) in June 2006 after complaining of
dyspnoea and a persistent cough. A chest X-ray showed
right pleural effusion and a further series of exams,
including high resolution computed tomography (HRCT),
confirmed a biphasic MPM. The patient had a known history
of hypertension, diabetes, abdominal aortic aneurism, and
exposure to asbestos.
In July 2006 the patient underwent talc pleurodesis and
started first-line chemotherapy with cisplatin associated
with pemetrexed (Alimta). At the end of the third
chemotherapy cycle the disease was stable and no signifi-
cant drug toxicity was recorded. For this reason, the
patient progressed through another three cycles under the
same treatment schedule. Restaging at the end of the sixth
cycle confirmed a stable disease and the patient started
follow-up.
In January 2007, further restaging showed disease
progression and the patient was enrolled in a phase I clin-
ical trial involving a continuous infusion of pemetrexed at
a dose of 100 mgm2 at day 1, every three weeks. Vitamin
B6 and B12 supplements together with a premedication of
prednisone were also included in the protocol to reduce the
toxicity. The first cycle, performed on 13 February, 2007 at
a dose of 150 mg (75% of the real dose), and the second
cycle, carried out on 6 March, 2007 at the full dose
(200 mg), did not induce any acute toxicity.
On 14 March 2007 the patient was referred to the Acci-
dent and Emergency Department for acute dyspnoea and
a fever of 38.5 C. On admission, a blood pressure of
140/90, a heart rate of 92 min1, and a SO2 of 78% were
recorded, and a left anterior hemiblock was diagnosed by
ECG. Laboratory exams revealed the following: leukocytes
2.89 106/mmc, neutrophils 1.04 106/mmc, platelets
1.01 105/mmc, haemoglobin 9.0 g/dl, glucose 139 mg/dl,
creatinine 1.5 mg/dl, LDH 855 U/l, fibrinogen 630 mg/dl,
and no pathogens were found in the peripheral blood hae-
moculture. A high resolution CT-scan of the thorax showed
diffuse, bilateral areas of ground glass attenuation with
a patchy distribution (Fig. 1).
A 13-day broad-spectrum antibiotic therapy did not
achieve any clinical and/or radiological improvement of
respiratory abnormalities, and for this reason a bronchos-
copy, with a fluoroscopic-guided transbronchial lung biopsy
(TBB), and a bronchoalveolar lavage (BAL), were per-
formed. BAL fluid analysis demonstrated 410 cells/mL3 with
52% macrophages, 12% lymphocytes, 35% neutrophils, 1%
eosinophils and a reverse CD4/CD8 ratio (1:2). BAL cultures
for common bacteria, acid fast bacilli and fungi, as well as
vial cultures and/or immunofluorescent tests for viruses(cytomegalovirus, adenovirus, herpes simplex virus,
syncytial respiratory virus, influenzae and parainfluenzae
viruses) and Legionellae, proved negative. Examination of
BAL cytospin preparations, stained by both Diff-Quick and
Papanicolaou methods, showed cuboidal hyperplastic/
dysplastic cells (diffuse alveolar damage cells) whilst no
malignant cells, viral inclusions, fungi, or Pneumocystis
jiroveci cysts were identified. The TBB showed remnants of
jaline membranes in the alveolar spaces along with granu-
lation tissue partly obliterating the alveolar spaces, and
slight thickening of the interalveolar septa. Plump elon-
gated reactive type II pneumocytes covering the alveolar
septa were also numerous (Fig. 2). A regimen of 200 mg
methylprednisolone once a day was started and a partial
remission of clinical and radiological abnormalities was
achieved. However the patient died after six months for
progression of neoplastic disease.
Pemetrexed is a multi-target folate inhibitor for the
second-line treatment of non-small cell lung cancer
(NSCLC),1 and MPM in combination or not with cisplatin.2,3
Neutropenia is the only common side effect of this well-
tolerated drug. Indeed, to the best of our knowledge, this is
the first report of an adverse pulmonary reaction to be
associated with this drug. Based on our clinical and
radiological findings, the differential diagnosis of the
Figure 2 Histologic finding of TBB: remnants of jaline
membranes in the alveolar spaces along with granulation tissue
partly obliterating the alveolar spaces, and slight thickening of
the interalveolar septa. Plump elongated reactive type II
pneumocytes covering the alveolar septa were also numerous.
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pathologic conditions, i.e.: infections, malignancies,
pulmonary alveolar haemorrhage, or drug-induced toxicity.
An infectious aetiology was ruled out by extensive micro-
biological studies. The hypothesis of malignancies, either
primary lung cancer (i.e. bronchioloalveolar carcinoma,
and mucosa-associated lymphoid tissue (MALT) lymphoma),
or metastatic mesothelioma involvement of the lung
parenchyma was easily excluded by examining the lung
biopsy.4e6 Furthermore, BAL and lung biopsy findings did
not support the diagnosis of pulmonary alveolar
haemorrhage.
Together with the careful exclusion of these possible
causes, several elements led to the suspicion that the lung
damage was caused by drug-induced toxicity. Firstly, both
cytological (BAL) and histological pulmonary findings,
although not specific, appear to support the diagnosis of
drug-induced toxicity.7 Secondly, for the prescription of
corticosteroids, which achieved a progressive remission of
clinico-radiological respiratory abnormalities after broad-spectrum antibiotics had failed to show any noticeable
improvement. Based on these observations we therefore
conclude that pemetrexed chemotherapy in continuous
infusion may cause acute lung toxicity.
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